Clinical Trial

Automated vs Manual Flow-cytometry Gating for Measurable Residual Disease in Acute Myeloid Leukaemia (DUALFLOW)

Study acronym: DUALFLOW
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This retrospective multicentre cohort evaluates the agreement of measurable residual disease (MRD) detection in acute myeloid leukaemia (AML) using two flow-cytometry gating approaches. Manual expert gating is compared with an unsupervised FlowSOM clustering algorithm across post-induction and post-consolidation samples from 50 adults and 10 paediatric patients treated at Bordeaux University Hospital. The primary hypothesis states that unsupervised gating detects MRD ≥ 0.1 % with sensitivity and specificity comparable to manual gating.
Trial Details
NCT Number NCT07269067
Lead Sponsor University Hospital, Bordeaux
Conditions Leukemia, Myeloid, Acute
Enrollment 60 participants
Start Date 2026-01
Primary Completion 2027-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2025-12-08